Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis | Synapse
March 3, 2026
Open Access
Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis
MR
Marina Romozzi
MP
Matteo Palermo
DD
Daisuke Danno
Tominaga hospital
Ver todo
Puntos clave
Anti-CGRP monoclonal antibodies improve outcomes in hemiplegic migraine.
Quantitative analysis of individual patients highlights significant benefits in migraine frequency.
Longitudinal data indicates sustained effectiveness and safety over time.
Findings suggest a viable treatment option for individuals suffering from hemiplegic migraine.
Leer artículo completo
externamente
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Cite This Study
Copy
Romozzi et al. (Fri,) studied this question.
synapsesocial.com/papers/69a75f8fc6e9836116a2b040
https://doi.org/https://doi.org/10.1186/s10194-026-02283-5